Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ranjit Dhaliwal (NPI 1851387245)

Field	Value
Entity Type	Individual
Organization	Ranjit Dhaliwal
Address	3520 Walton Way Ext
City	Augusta
State	GA
ZIP	30909
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	September 21, 2005

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the available data: Total Medicare revenue is $1.9M and there is no Medicaid billing on file. That makes Medicare the dominant — effectively only — public payer in this profile, so analyses of scale and risk should focus on Medicare reimbursement patterns.

Revenue is heavily concentrated in a few intravitreal drug codes: the precomputed top 3 Medicare codes by revenue account for 69.9% of the provider's total Medicare revenue, led by J0178 at $1.1M (55.8% of total Medicare revenue). The next two top contributors are J2777 ($142.7K, 7.4%) and J2778 ($128.8K, 6.7%), so changes in anti‑VEGF drug utilization, coverage, or pricing would materially affect overall revenue.

The code mix and volumes indicate a retina‑focused practice centered on medical retina care with a surgical component: high volumes of intravitreal drug injections (J0178, J2777, J2778, Q5128) together with extensive retinal imaging (92134) and notable vitrectomy codes (67041, 67042) point to a combined medical and surgical retinal service line rather than a general ophthalmology clinic. This pattern is consistent with a retina specialist delivering repeated pharmacologic therapy and diagnostic follow‑up for posterior‑segment disease.

Competitive standing for anti‑VEGF use is mixed: J0178 (aflibercept) ranks #777 of 3204 providers nationally (76th percentile), which is a typical but not dominant national volume for that drug, while J2777 (faricimab) ranks #1541 of 2039 (24th percentile) and J2778 (ranibizumab) ranks #569 of 1208 (53th percentile), indicating moderate use of multiple agents but no clear national dominance across all biologics. These rank/percentile signals suggest a solid regional presence for aflibercept with more modest adoption or share for other agents.

Diagnostic and E/M throughput is a notable strength: 92134 (retinal imaging) is an extreme outlier at the national level (2.4K claims, $66K revenue, ranks #694 of 26868, 97th percentile), and office E/M codes 99214 and 99213 are both notably above typical national volume (96th and 97th percentiles respectively). Together these data indicate high imaging and follow‑up visit volume, consistent with managing chronic retinal disease and frequent post‑injection monitoring.

Surgical retina activity is above typical for peers: 67041 (vitrectomy with membrane peel) shows 55 claims and $47K revenue and ranks #19 of 461 providers nationally (96th percentile, notably above typical national volume). This high percentile suggests the provider performs surgical retinal procedures at a higher rate than most peers, supporting a mixed medical‑surgical retina practice model rather than purely injection‑only care.

Ancillary and high‑cost drug billing is present but concentrated: J3490 (unclassified drugs) has 35 claims with a $2063 average paid/claim and $72.2K revenue (3.7% of Medicare revenue) but ranks relatively low nationally (26th percentile), while Q5128 (ranibizumab biosimilar) contributes $84.8K (4.4% of revenue) at a 34th percentile rank. These entries point to occasional billing for high‑cost or specialty pharmaceutical items and biosimilars, which are material to revenue but do not reflect broad national leadership in such items.

The provider has long tenure in Medicare billing, with an NPI enumerated 2005-09-21 (~21 years ago), indicating an established practice footprint and multi‑year operational history that aligns with the sustained injection, imaging, and surgical volumes seen in the Medicare file. This longevity supports interpreting current patterns as stable practice behavior rather than short‑term fluctuation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

26 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	1,560	$690	$1.1M
J2777	Injection, faricimab‑svoa, 0.1 mg	4,920	$30	$142.7K
J2778	Injection, ranibizumab, 0.1 mg	700	$180	$128.8K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,200	$80	$94.8K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	390	$220	$84.8K
J3490	Unclassified drugs	40	$2,060	$72.2K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	2,450	$30	$66K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	840	$80	$64.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	740	$60	$47.2K
67041	In this procedure, the provider removes scar tissue from the retinal membrane that obscures vision. He removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical…	60	$860	$47K

Showing 1–10 of 26

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 26 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Ranjit Dhaliwal — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

26 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	13	70	970	$680	$700.6K
J2777	38	40	14,100	$30	$524.3K
J2778	19	30	1,170	$180	$286.2K
Q5128	2	10	390	$220	$98.6K
67028	24	80	720	$90	$71.9K
67042	6	20	20	$1,200	$31.1K
67041	1	10	10	$1,140	$30.7K
J3490	38	50	50	$320	$19.8K
92014	293	850	130	$80	$19.7K
99214	528	13,640	120	$80	$17.8K

Showing 1–10 of 26

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ranjit Dhaliwal, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Joshua Robinson	MI	Ophthalmology Physician	$3.7M	$0
William Clark	SC	Ophthalmology Physician	$3.3M	$0
Barron Fishburne	SC	Retina Specialist (Ophthalmology) Physician	$3.3M	$0
Jeffrey Gross	SC	Retina Specialist (Ophthalmology) Physician	$3M	$0
David Johnson	SC	Retina Specialist (Ophthalmology) Physician	$3M	$0
Oksana Demediuk	GA	Retina Specialist (Ophthalmology) Physician	$2.9M	$0
Daniel Will	SC	Retina Specialist (Ophthalmology) Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Ranjit Dhaliwal, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Faircloth Bakeman Partnership	GA	Oral and Maxillofacial Surgery (Dentist)	$0	$4M
Augusta Obstetrics And Gynecology Specialists, LLC	GA	Obstetrics & Gynecology Physician	$0	$3.7M
Eye Surgery Center Of Augusta, LLC	GA	Ambulatory Surgical Clinic/Center	$3.2M	$0
Pediatricare Pm	GA	Pediatrics Physician	$0	$2.8M
Doctors Hospital Of Augusta LLC	GA	General Acute Care Hospital	$0	$2.2M
Joseph M Still Burn Centers, Inc	GA	Specialist	$0	$2M
Eugene Long	GA	Hematology & Oncology Physician	$1.9M	$0
Dennis Marcus	GA	Ophthalmology Physician	$1.8M	$0
David Squires	GA	Hematology & Oncology Physician	$1.6M	$0
Aos Surgery Center LLC	GA	Ambulatory Surgical Clinic/Center	$1.1M	$0

Ranjit Dhaliwal — Billing Profile & Reimbursement Data

Sign up for Ranjit Dhaliwal — Billing Profile & Reimbursement Data policy alerts

Ranjit Dhaliwal — Billing Profile & Reimbursement Data

Sign up for Ranjit Dhaliwal — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References